Study on the efficacy and safety of Xueyou Mixture (血友合剂) in treating hemophilia

Liu  Shan-xi; Jiang Lin; Liu Yi-guo; He Yue-qin; Liang Xin; Kong Wei-wei; Chen Jing

doi:10.1007/s11655-007-0141-6

Your Location：

Home >

Browse articles >

Study on the efficacy and safety of Xueyou Mixture (血友合剂) in treating hemophilia

OriginalPaper | Updated：2021-08-27

- Study on the efficacy and safety of Xueyou Mixture (血友合剂) in treating hemophilia
- Study on the efficacy and safety of Xueyou Mixture (血友合剂) in treating hemophilia
- 中国结合医学杂志（英文版） 2007年13卷第2期页码：141-144
- Affiliations：
  
  Shanxi YiDa Institute of Hematopathy,Xi’an,China
- Author bio：
- Funds：
- DOI：10.1007/s11655-007-0141-6
  中图分类号：
- 纸质出版日期：2007，
Scan for full text
Liu, Sx., Jiang, L., Liu, Yg. et al. Study on the efficacy and safety of Xueyou Mixture (血友合剂) in treating hemophilia., Chin. J Integ. Med. 13, 141–144 (2007). https://doi.org/10.1007/s11655-007-0141-6

Liu Shan-xi, Jiang Lin, Liu Yi-guo, et al. Study on the efficacy and safety of Xueyou Mixture (血友合剂) in treating hemophilia[J]. Chinese Journal of Integrative Medicine, 2007,13(2):141-144.
Liu, Sx., Jiang, L., Liu, Yg. et al. Study on the efficacy and safety of Xueyou Mixture (血友合剂) in treating hemophilia., Chin. J Integ. Med. 13, 141–144 (2007). https://doi.org/10.1007/s11655-007-0141-6 DOI：

Liu Shan-xi, Jiang Lin, Liu Yi-guo, et al. Study on the efficacy and safety of Xueyou Mixture (血友合剂) in treating hemophilia[J]. Chinese Journal of Integrative Medicine, 2007,13(2):141-144. DOI： 10.1007/s11655-007-0141-6.

摘要

To observe the effect of Xueyou Mixture (血友合剂

XYM) on blood coagulation factors and its safety in treating hemophilia. To the randomly selected 65 inpatients of hemophilia

XYM was administered accompanied with intravenous dripping of liver cell growth factor 60–100 mg once a day to protect the liver

with no blood products like concentrated VIII and FIX factors or blood plasma given. The treatment lasted for 3 weeks. The short-term efficacy and adverse reactions were observed. The long-term efficacy in patients was observed in a follow-up study of 6–12 months after they were discharged from the hospital but continuously took XYM orally. The short-term markedly effective rate in the patients was 95.38% (62/65). After they were treated for 3 weeks

the level of FVIII factor activity increased in 56 patients of type A from (3.32±2.21) % to (4.18±2.23) %

and in 9 of type B from (4.92±1.81) % to (5.64±1.96) %. Compared with that before treatment

the difference was signifi cant in both of them (P<0.01). No obvious adverse reaction was found in the treatment period. The follow-up study showed that in 22 patients of type A

the FVIII factor activity ratio increased from (3.25±2.11) % to (6.31±2.16) %

(8.36±1.05) %

and (16.38±2.71) % in the 2nd

3rd and 6th month after discharge respectively

all showing significant difference to that before treatment (P<0.01); and in 4 patients of type B

it increased from (4.15±2.26) % to 7.8% and 11.6% (mean value) in the 2nd and 6th month respectively. XYM could raise the activity of factors VIII and IX in patients with hemophilia

and the degree of the rise is related with the duration of the therapy

with no obvious adverse reaction

which strikes out a new path and new train of thinking for the treatment of the disease by nonblood preparation.

Abstract

To observe the effect of Xueyou Mixture (血友合剂

XYM) on blood coagulation factors and its safety in treating hemophilia. To the randomly selected 65 inpatients of hemophilia

XYM was administered accompanied with intravenous dripping of liver cell growth factor 60–100 mg once a day to protect the liver

the level of FVIII factor activity increased in 56 patients of type A from (3.32±2.21) % to (4.18±2.23) %

and in 9 of type B from (4.92±1.81) % to (5.64±1.96) %. Compared with that before treatment

the difference was signifi cant in both of them (P<0.01). No obvious adverse reaction was found in the treatment period. The follow-up study showed that in 22 patients of type A

the FVIII factor activity ratio increased from (3.25±2.11) % to (6.31±2.16) %

(8.36±1.05) %

and (16.38±2.71) % in the 2nd

3rd and 6th month after discharge respectively

all showing significant difference to that before treatment (P<0.01); and in 4 patients of type B

it increased from (4.15±2.26) % to 7.8% and 11.6% (mean value) in the 2nd and 6th month respectively. XYM could raise the activity of factors VIII and IX in patients with hemophilia

and the degree of the rise is related with the duration of the therapy

with no obvious adverse reaction

which strikes out a new path and new train of thinking for the treatment of the disease by nonblood preparation.

关键词

Xueyou Mixturehemophiliatherapeutic efficacy

Keywords

Xueyou Mixturehemophiliatherapeutic efficacy

references

Ye SG, editor. Internal medicine. 6th ed. Beijing: People’s Medical Publishing House, 2004:663–666.

Arruda VR, Schuettrumpf J, Herzog RW, et al. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adenoassociated viral vector serotype I. Blood 2004;103:85–92.

Follenzi A, Battaglia M, Lombardo A, et al. Targeting ientiviral vector expression to hepatocytes limits transgenespecific immune response and establishes long-term expression of human antihemophilic factor IX in mice. Blood 2004; 103:3700–3709.

Gilles JG, Grailly SC, Maeyer M, et al. In vivo neutralization of a C2 domain-specific human anti-Factor VIII inhibitor by an anti-idiotypic antibody. Blood 2004; 103(7):2617–2623.

Zhang ZN, editor. Standard for diagnosis and treatment of blood disease. 2nd ed. Beijing: Science Press, 1998:304–311.

Fay PJ, Jenkins PV. Mutating factor VIII: lessons from structure to function. Blood Rev 2005; 19:15–27.

Rodriguez MH, Plantier JL, Enjolras N, et al. Biosynthesis of FVIII in megakaryocytic cells: improved production and biochemical characterization. Br J Haematol 2004;127:568–575.

Mohanty D, Ghosh K, Shetty S, et al. Mutations in the MCFD2 gene and a novel mutation in the LMAN 1 gene in Indian families with combined defi ciency of factor V and VIII. Am J Hematol 2005; 79:262–266.

Nakaya SM, Hsu TC, Geraghty SJ, et al. Severe hemophilia A due to a 1.3 kb factor VIII gene deletion including exon24: homologous recombination between 41 bp within an Alu repeat sequence in introns 23 and 24. J Thromb Haemost 2004; 2:1941–1945.

Spiegel PC, Murphy P, Stoddard BL. Surface-exposed hemophilic mutations across the factor VIIIC2 domain have variable effects on stability and binding activities. J Biol Chem 2004; 279:53691–53698.

Nogami K, Freas J, Manithody C, et al. Mechanisms of interactions of factor X and factor Xa with the acidic region in the factor VIII A1 domain. J Biol Chem 2004; 279:33104–33113.

Shen PA, editor. Traditional Chinese medicine pharmacology and clinical appliance. Beijing: People’s Medical Publishing House, 2006: 75–80, 95–98, 829–832, 822–825.

FULL TEXT LINK

More>

浏览量

309

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

De-qi, not psychological factors, determines the therapeutic efficacy of acupuncture treatment for primary dysmenorrhea